Evelyn Wang, Ph.D. joined Circle in July 2021 as our VP of Translational Medicine. Prior to Circle, Dr. Wang led Translational Medicine at Exelixis, Inc. where she built a translational team to handle diverse large data analysis from global clinical programs. She oversaw establishment of pharmacodynamic and biomarker strategies for clinical trials, evaluated and coordinated the correlative research for investigator sponsored studies, and established nonclinical/preclinical studies in support of development strategies and research. Programs included Cabozantinib and immune-oncology combination studies, and other small and large molecule programs. At Biomarin Pharmaceutical Inc., she led translational research for Talazoparib and rare genetic disease programs. Prior to Biomarin, she was at Exelixis where she was the translational medicine lead for several oncology pipeline drugs. Earlier experience includes academic and startup environments. She completed her M.S. and Ph.D. at New York University Medical Center and her postdoctoral training at Harvard Medical School.